US DoJ warns medtech industry of global bribery crackdown
This article was originally published in Clinica
The US Department of Justice is carrying out a formal investigation into the entire medical technology industry to “root out” behaviour that violates the Foreign Corrupt Practices Act. In addition, the department’s foreign counterparts are stepping up their anti-bribery enforcement efforts. Therefore, companies need to increase their focus on foreign bribery compliance. So said Kathleen Hamann, a trial attorney in the fraud section of the DoJ’s Criminal Division, who was speaking at the 2010 International Medical Device Industry Compliance Conference taking place this week in Berlin, Germany.